Overview

A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of JNJ-54861911 during 6 months of treatment in participants with early (predementia) alzheimer's disease (AD [degenerative disease of the brain characterized by the insidious onset of dementia, impairment of memory, judgment, attention span, and problem solving skills are followed by severe apraxias and a global loss of cognitive abilities]).
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC